These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 19384429)

  • 21. Cancer biomarker discovery and translation: proteomics and beyond.
    Hristova VA; Chan DW
    Expert Rev Proteomics; 2019 Feb; 16(2):93-103. PubMed ID: 30556752
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Advances in ovarian cancer proteomics: the quest for biomarkers and improved therapeutic interventions.
    Jurisicova A; Jurisica I; Kislinger T
    Expert Rev Proteomics; 2008 Aug; 5(4):551-60. PubMed ID: 18761466
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Proteomic Approaches for Biomarker Panels in Cancer.
    Tanase C; Albulescu R; Neagu M
    J Immunoassay Immunochem; 2016; 37(1):1-15. PubMed ID: 26565430
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diagnostic and Prognostic Biomarkers in ovarian cancer and the potential roles of cancer stem cells - An updated review.
    Muinao T; Deka Boruah HP; Pal M
    Exp Cell Res; 2018 Jan; 362(1):1-10. PubMed ID: 29079264
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quantitative proteomic analysis of human plasma using tandem mass tags to identify novel biomarkers for herpes zoster.
    Wang T; Shen H; Deng H; Pan H; He Q; Ni H; Tao J; Liu S; Xu L; Yao M
    J Proteomics; 2020 Aug; 225():103879. PubMed ID: 32585426
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ovarian cancer in the proteomics era: diagnosis, prognosis, and therapeutics targets.
    Boyce EA; Kohn EC
    Int J Gynecol Cancer; 2005; 15 Suppl 3():266-73. PubMed ID: 16343243
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Breast cancer classification by proteomic technologies: current state of knowledge.
    Lam SW; Jimenez CR; Boven E
    Cancer Treat Rev; 2014 Feb; 40(1):129-38. PubMed ID: 23891266
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials.
    Meagher NS; Schuster K; Voss A; Budden T; Pang CNI; deFazio A; Ramus SJ; Friedlander ML
    Gynecol Oncol; 2018 Sep; 150(3):527-533. PubMed ID: 30054102
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genomic and proteomic biomarkers for cancer: a multitude of opportunities.
    Tainsky MA
    Biochim Biophys Acta; 2009 Dec; 1796(2):176-93. PubMed ID: 19406210
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mass spectrometry-based clinical proteomics: head-and-neck cancer biomarkers and drug-targets discovery.
    Matta A; Ralhan R; DeSouza LV; Siu KW
    Mass Spectrom Rev; 2010; 29(6):945-61. PubMed ID: 20945361
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ovarian Cancer Biomarkers: Moving Forward in Early Detection.
    Bonifácio VDB
    Adv Exp Med Biol; 2020; 1219():355-363. PubMed ID: 32130708
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunohistochemistry in the Diagnosis of Mucinous Neoplasms Involving the Ovary: The Added Value of SATB2 and Biomarker Discovery Through Protein Expression Database Mining.
    Strickland S; Wasserman JK; Giassi A; Djordjevic B; Parra-Herran C
    Int J Gynecol Pathol; 2016 May; 35(3):191-208. PubMed ID: 26535987
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proteomic approaches in lung cancer biomarker development.
    Cho JY; Sung HJ
    Expert Rev Proteomics; 2009 Feb; 6(1):27-42. PubMed ID: 19210125
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Proteomic profiling identifies afamin as a potential biomarker for ovarian cancer.
    Jackson D; Craven RA; Hutson RC; Graze I; Lueth P; Tonge RP; Hartley JL; Nickson JA; Rayner SJ; Johnston C; Dieplinger B; Hubalek M; Wilkinson N; Perren TJ; Kehoe S; Hall GD; Daxenbichler G; Dieplinger H; Selby PJ; Banks RE
    Clin Cancer Res; 2007 Dec; 13(24):7370-9. PubMed ID: 18094419
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biomarker discovery in epithelial ovarian cancer by genomic approaches.
    Mok SC; Elias KM; Wong KK; Ho K; Bonome T; Birrer MJ
    Adv Cancer Res; 2007; 96():1-22. PubMed ID: 17161674
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mass spectrometry-based proteomic profiling of lung cancer.
    Ocak S; Chaurand P; Massion PP
    Proc Am Thorac Soc; 2009 Apr; 6(2):159-70. PubMed ID: 19349484
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CD44 as a cancer stem cell marker and its prognostic value in patients with ovarian carcinoma.
    Bartakova A; Michalova K; Presl J; Vlasak P; Kostun J; Bouda J
    J Obstet Gynaecol; 2018 Jan; 38(1):110-114. PubMed ID: 28816557
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Proteomics of cancer of hormone-dependent tissues.
    Tyson DR; Ornstein DK
    Adv Exp Med Biol; 2008; 630():133-47. PubMed ID: 18637489
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comprehensive Analysis of Cancer-Proteogenome to Identify Biomarkers for the Early Diagnosis and Prognosis of Cancer.
    Shukla HD
    Proteomes; 2017 Oct; 5(4):. PubMed ID: 29068423
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ovarian cancer: markers of response.
    Na YJ; Farley J; Zeh A; del Carmen M; Penson R; Birrer MJ
    Int J Gynecol Cancer; 2009 Dec; 19 Suppl 2():S21-9. PubMed ID: 19955910
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.